Evusheld was designed to protect immunocompromised people from serious cases of COVID-19, but the latest Omicron variants have rendered the drug useless
, a medication that was once a valuable tool for preventing patients with weakened immune systems from becoming severely ill with COVID-19.the biological drug should no longer be used.
— 7.2 million adults — is thought to have immune deficiencies that put them at risk of becoming severely ill or dying if they are infected with the pandemic virus., an infectious disease doctor at Massachusetts General Hospital who cares for people with impaired immunity. For her patients, she said, “it was kind of like being told the seat belts in your car won’t work anymore, and we’re not going to be able to replace them with anything.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Leer más »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Leer más »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Leer más »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Leer más »
U.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment EvusheldThe U.S. health regulator has withdrawn emergency-use authorization for AstraZeneca's COVID-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.
Leer más »
FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariantsMany take Evusheld as an additional layer of protection because the vaccines do not trigger a strong immune response for them.
Leer más »